For two decades, researchers debated whether adeno-associated viruses, the small viruses used to deliver new genes to thousands of patients, could, in some cases, cause tumors. This debate is over.
A series of cases this year presented strong evidence that adeno-associated viruses, or AAVs, can cause cancer, forcing researchers and families to weigh the newly confirmed risk against the technology’s lifesaving potential — and, hopefully, determine how to design better therapies in the future.
“It’s going to change the calculus for some patients,” said Sam Mackenzie, a neurologist at the University of Rochester, speaking specifically about spinal muscular atrophy patients.
This article is reserved for STAT+ subscribers
Unlock this article – plus daily coverage and analysis of the biotech sector – by subscribing to STAT+.
Already have an account? Log in
See all packages
To read the rest of this story, subscribe to STAT+.
Subscribe
Gn bussni
